3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Ovarian Neoplasms
3
Breast Neoplasms
3
Neoplasms
2
Uterine Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Salivary Gland Neoplasms
1
Prostatic Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms, Unknown Primary
1
Neoadjuvant Therapy
1
Lung Neoplasms
1
Kenny-Caffey syndrome, Type 1
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Biliary Tract Neoplasms
1
Adenocarcinoma
1
Interventions
Oxaliplatin
200
Capecitabine
116
S 1 (combination)
106
Fluorouracil
105
Docetaxel
100
Cisplatin
88
Leucovorin
75
Paclitaxel
71
Irinotecan
68
apatinib
43
sintilimab
42
Drug Therapy
42
Surgical Procedures, Operative
37
Hyperthermic Intraperitoneal Chemotherapy
34
pembrolizumab
32
Radiotherapy
31
Trastuzumab
30
Gastrectomy
23
Nivolumab
22
Epirubicin
22
Tegafur
21
Bevacizumab
21
XELOX
20
titanium silicide
19
camrelizumab
19
tislelizumab
17
Ramucirumab
17
Carboplatin
16
Neoadjuvant Therapy
15
Endoscopic Mucosal Resection
15
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Stomach Neoplasms
×
Poly(ADP-ribose) Polymerase Inhibitors
×
Clear all
NCT04584008
2024-10-15
VISIONARY
Peking University
Phase NA
Active not recruiting
600 enrolled